Sudden Cardiac Death. An Essay for 2008

https://doi.org/10.1016/j.pcad.2007.11.002Get rights and content

Section snippets

Prologue

Sudden cardiac death (SCD) has been an acquaintance, but not quite a friend, for nearly my entire professional life. Early in my career, in 1980, with my colleague and chief, Dr. Edward M. Dwyer, Jr., I planned a conference on Sudden Coronary Death sponsored by the New York Academy of Sciences. The conference was held in 1981 and published in 1982.1 Now, 25 years later, if not at the end, certainly late in my career, I am again participating in the planning of a symposium on Sudden Cardiac

The Stage

From a clinician's vantage point, sudden cardiac death can be trifurcated into distinct categories each of which requires unique insights into management and prevention.

The first category is that of the desperately sick heart. Initially the focus was limited to the coronary patient, defining high risk as prior aborted sudden death or easily induced malignant arrhythmia, but ultimately patients with an EF <30% due to myocardial infarction dominated the systematic enrollment into clinical trials.4

The Current Players

The bottom three steps of Myerburg's ziggurat embrace patients easiest to identify as SCD candidates, those with very sick hearts. Step 6, patients with an EF <30% and a prior myocardial infarction, are MADIT II patients4; step 4 patients, those with congestive heart failure and an EF <35%, are the population for SCD-Heft5 and for those patients with a prolonged QRS duration, the currently enrolling MADIT CRT.16 Patients in Step 5, those with prior out-of-hospital aborted sudden death or some

The Next Act

In the 1980's categories of risk were beginning to be defined and mechanisms were tentatively proposed. The search for mechanisms of SCD genesis and mechanisms of intervention was the dominant theme of the 1981 conference. Much of the focus was on electrical instability, but coronary spasm, platelet function, and autonomic nervous system dysfunction were all considered fruitful areas of inquiry. The intervention spotlight focused on drugs, although the ICD had begun to creep on to the stage.

First page preview

First page preview
Click to open first page preview

References (39)

  • Risk Stratification and Survival After Myocardial Infarction

    New Eng J Med

    (1983)
  • A.J. Moss et al.

    Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced EF

    New Engl J Med

    (2002)
  • G.H. Bardy et al.

    (SCH-Heft) Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure

    N Engl J Med

    (2005)
  • P.J. Schwartz et al.

    Genotype-phenotype correlations in the long-QT syndrome: gene-specifc triggers for life threatening arrhythmias

    Circulation

    (2001)
  • R. Brugada et al.

    Sudden death associated with short-QT syndrome linked to mutations in HERG

    Circulation

    (2004)
  • S.G. Priori et al.

    Clinical and genetic heterogeneity of right bundle branch block and ST-segment elevation syndrome

    Circulation

    (2000)
  • S. Priori et al.

    Role of genetic analysis in cardiology

    Part 1: Mendelian diseases: cardiac channelopathies. Circulation

    (2006)
  • K. Pilichou et al.

    Mutations in desmoglein-2 gene are associated with arrhythmogenic right ventricular cardiomyopathy

    Circulation

    (2006)
  • P. Richard et al.

    Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy

    Circulation

    (2003)
  • View full text